Reviva Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the recipient of unusually large options trading on Thursday. Stock investors acquired 4,052 call options on the company. This represents an increase of 103% compared to the typical volume of 1,999 call options.

Institutional Trading of Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the SEC. Institutional investors own 63.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, EF Hutton Acquisition Co. I raised Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 23rd.

Reviva Pharmaceuticals Trading Up 2.2 %

NASDAQ RVPH traded up $0.04 on Thursday, hitting $1.85. 637,940 shares of the company were exchanged, compared to its average volume of 796,415. Reviva Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $5.67. The company has a market cap of $61.87 million, a PE ratio of -1.67 and a beta of -0.02. The stock has a fifty day moving average of $1.45 and a 200-day moving average of $1.26.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.